American International Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-86,593
| Closed | -$62K | – | 3088 |
|
|
2022
Q1 | $62K | Sell |
86,593
-6,095
| -7% | -$13K | ﹤0.01% | 2769 |
|
|
2021
Q4 | $209K | Sell |
92,688
-2,773
| -3% | -$7.56K | ﹤0.01% | 2342 |
|
|
2021
Q3 | $275K | Buy |
95,461
+5,923
| +7% | +$16.9K | ﹤0.01% | 2228 |
|
|
2021
Q2 | $339 | Buy |
89,538
+6,066
| +7% | +$20.4K | ﹤0.01% | 2174 |
|
|
2021
Q1 | $283 | Buy |
83,472
+220
| +0.3% | +$792 | ﹤0.01% | 2171 |
|
|
2020
Q4 | $233 | Sell |
83,252
-2,388
| -3% | -$6.97K | ﹤0.01% | 2198 |
|
|
2020
Q3 | $215K | Buy |
85,640
+6,029
| +8% | +$52.9K | ﹤0.01% | 2102 |
|
|
2020
Q2 | $1.08M | Buy |
79,611
+9,724
| +14% | +$101K | 0.01% | 1179 |
|
|
2020
Q1 | $530K | Sell |
69,887
-4,039
| -5% | -$31.4K | ﹤0.01% | 1399 |
|
|
2019
Q4 | $467K | Sell |
73,926
-622
| -0.8% | -$2.96K | ﹤0.01% | 1726 |
|
|
2019
Q3 | $292K | Sell |
74,548
-520
| -0.7% | -$2.23K | ﹤0.01% | 1948 |
|
|
2019
Q2 | $363K | Buy |
75,068
+20,354
| +37% | +$116K | ﹤0.01% | 1884 |
|
|
2019
Q1 | $448K | Sell |
54,714
-1,772
| -3% | -$12.2K | ﹤0.01% | 1777 |
|
|
2018
Q4 | $312K | Buy |
56,486
+23,038
| +69% | +$180K | ﹤0.01% | 1927 |
|
|
2018
Q3 | $295K | Buy |
33,448
+602
| +2% | +$5.38K | ﹤0.01% | 2182 |
|
|
2018
Q2 | $328K | Buy |
32,846
+4,233
| +15% | +$42.4K | ﹤0.01% | 2089 |
|
|
2018
Q1 | $273K | Sell |
28,613
-1,538
| -5% | -$21.5K | ﹤0.01% | 2080 |
|
|
2017
Q4 | $448K | Buy |
30,151
+431
| +1% | +$7.15K | ﹤0.01% | 1853 |
|
|
2017
Q3 | $585K | Buy |
29,720
+6,836
| +30% | +$105K | ﹤0.01% | 1659 |
|
|
2017
Q2 | $329K | Buy |
22,884
+763
| +3% | +$9.67K | ﹤0.01% | 1978 |
|
|
2017
Q1 | $204K | Buy |
22,121
+1,460
| +7% | +$14.3K | ﹤0.01% | 2170 |
|
|
2016
Q4 | $215K | Sell |
20,661
-54
| -0.3% | -$465 | ﹤0.01% | 2132 |
|
|
2016
Q3 | $187K | Buy |
20,715
+31
| +0.1% | +$264 | ﹤0.01% | 2210 |
|
|
2016
Q2 | $155K | Buy |
20,684
+6,405
| +45% | +$55.9K | ﹤0.01% | 2321 |
|
|
2016
Q1 | $129K | Hold |
14,279
| – | – | ﹤0.01% | 3191 |
|
|
2015
Q4 | $184K | Sell |
14,279
-25
| -0.2% | -$255 | ﹤0.01% | 2931 |
|
|
2015
Q3 | $138K | Buy |
14,304
+17
| +0.1% | +$156 | ﹤0.01% | 3159 |
|
|
2015
Q2 | $147K | Buy |
14,287
+9,361
| +190% | +$79.9K | ﹤0.01% | 3311 |
|
|
2015
Q1 | $54.7K | Hold |
4,926
| – | – | ﹤0.01% | 3925 |
|
|
2014
Q4 | $57.3K | Sell |
4,926
-195
| -4% | -$2.8K | ﹤0.01% | 3910 |
|
|
2014
Q3 | $113K | Sell |
5,121
-3
| -0.1% | -$69 | ﹤0.01% | 3450 |
|
|
2014
Q2 | $142K | Buy |
+5,124
| New | +$123K | ﹤0.01% | 3297 |
|
Other funds holding AKBA
AIM
HF
American International Group's AKBA Position: Q2 2022 in Review
American International Group sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 86,593 shares — an estimated $62K sold.
American International Group first reported a position in AKBA in Q2 2014 and held it in 32 quarters. The position peaked at $1.08M in Q2 2020. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.
- American International Group reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
- American International Group sold 86,593 Akebia Therapeutics shares in Q2 2022, an estimated $62K.
- American International Group first reported a position in Akebia Therapeutics in Q2 2014 and held it in 32 quarters.
- American International Group's Akebia Therapeutics position peaked at $1.08M in Q2 2020.
- 96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.
Based on American International Group's 13F filing for Q2 2022, filed 12 Aug 2022.